Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia.
about
Cardiovascular Complications of PregnancyAngiogenic factors in preeclampsia: potential for diagnosis and treatmentThe use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome.Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia.Is massive proteinuria associated with maternal and fetal morbidities in preeclampsia?Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia.Plasma from preeclamptic women increases blood-brain barrier permeability: role of vascular endothelial growth factor signaling.Unexplained fetal death is associated with increased concentrations of anti-angiogenic factors in amniotic fluidAn imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study.Protein profiling of preeclampsia placental tissuesPreeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohortMaternal plasma concentrations of sST2 and angiogenic/anti-angiogenic factors in preeclampsia.Circulating angiogenic and antiangiogenic factors in women with eclampsia.Evidence in support of a role for anti-angiogenic factors in preterm prelabor rupture of membranes.Aspirin inhibits expression of sFLT1 from human cytotrophoblasts induced by hypoxia, via cyclo-oxygenase 1.Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practiceBiochemical markers for prediction of preclampsia: review of the literature.Gene expression profiling of placentae from women with early- and late-onset pre-eclampsia: down-regulation of the angiogenesis-related genes ACVRL1 and EGFL7 in early-onset diseaseLate-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion.Leukocytes of pregnant women with small-for-gestational age neonates have a different phenotypic and metabolic activity from those of women with preeclampsia.Fetal death: a condition with a dissociation in the concentrations of soluble vascular endothelial growth factor receptor-2 between the maternal and fetal compartments.A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsiaA subset of patients destined to develop spontaneous preterm labor has an abnormal angiogenic/anti-angiogenic profile in maternal plasma: evidence in support of pathophysiologic heterogeneity of preterm labor derived from a longitudinal study.Complement Split Products in Amniotic Fluid in Pregnancies Subsequently Developing Early-Onset PreeclampsiaLow placental growth factor across pregnancy identifies a subset of women with preterm preeclampsia: type 1 versus type 2 preeclampsia?Placental endoplasmic reticulum stress negatively regulates transcription of placental growth factor via ATF4 and ATF6β: implications for the pathophysiology of human pregnancy complicationsThe role of angiogenic, anti-angiogenic and vasoactive factors in pre-eclamptic African women: early- versus late-onset pre-eclampsiaPotential markers of preeclampsia--a review.Mechanism of hypoxia-induced GCM1 degradation: implications for the pathogenesis of preeclampsia.Early Prognostic Factors for the Progress of Preeclampsia - Our Experience in the Period 2010-2011.Evidence of an imbalance of angiogenic/antiangiogenic factors in massive perivillous fibrin deposition (maternal floor infarction): a placental lesion associated with recurrent miscarriage and fetal death.First trimester biomarkers in the prediction of later pregnancy complications.Dynamic proteome in enigmatic preeclampsia: an account of molecular mechanisms and biomarker discovery.New directions in the prediction of pre-eclampsia.The prediction of late-onset preeclampsia: Results from a longitudinal proteomics study.Racial-ethnic differences in midtrimester maternal serum levels of angiogenic and antiangiogenic factors.Pregnancy Outcome in Women with Obstetric and Thrombotic Antiphospholipid Syndrome-A Retrospective Analysis and a Review of Additional Treatment in Pregnancy.Urinary Polycyclic Aromatic Hydrocarbon Metabolite Associations with Biomarkers of Inflammation, Angiogenesis, and Oxidative Stress in Pregnant Women.Anti-angiogenesis and Preeclampsia in 2016.PlGF enhances TLR-dependent inflammatory responses in human mononuclear phagocytes.
P2860
Q26782481-891A3A3A-E8EF-40EE-AED8-7AA5B8C2B5C8Q26825774-3D23E131-AD37-4792-AFB4-6BBCDCD2008EQ33385942-8812DE5C-C384-4634-BF19-A8D3E1FC26C3Q33438425-EE546742-C25B-495E-82FC-FB4AF8135ED9Q33711849-40B7DEA6-923E-4783-BA35-6E024350A2BAQ33863973-5A06E092-5333-44C0-9FC7-B97CB75884C0Q34222231-FE7EB68A-780D-4907-AA49-4D7A054DB039Q34470845-FC35D635-7CC5-41A6-936C-944CE8486B1BQ34505090-499EAAA1-A13B-4385-A754-6D52CE8E086CQ34506462-C120006A-45F1-4B7F-A778-CCB14949EE99Q34567015-3B9B8E7F-C6DF-49DD-935B-170520EF0BE0Q34619975-052AB319-50E4-4487-A295-7FF621171795Q34670638-B01CA5AE-5433-466E-9904-56E841387A63Q35015402-CFC77A2E-CAEE-418C-A14B-41C36753DB55Q35178348-77B79FAC-1D48-407F-A72B-B7DCCC65B832Q35204444-E7C3374A-3386-4330-A4B9-BDBE489ECADBQ35756049-3F24853C-F21A-41D7-BE1A-02220B07AEC3Q35797381-5DC07781-26D6-4087-8592-4A87D3FE0CB6Q36107337-D109EF04-7DFF-4B74-AB7F-46C7D8D9453CQ36185268-CD5C19CF-3D04-44E1-81CE-A38E423B1F5CQ36189578-EA82AC82-CABD-43EA-90C3-1FBD5A448933Q36221448-288A2B8B-223C-44CE-A786-8636FB2DDD14Q36221487-3CC85AD2-5BB2-4403-A213-0F3939458641Q36236265-4DC78E22-F976-43C5-99DC-DCD3364A7456Q36626307-D22E43A5-1B4D-4AE9-BB26-C27794E34BAAQ36667589-D0399D0F-63EF-4B57-833F-DC34D6AA0424Q37041658-EB89151C-CFE8-484D-B27E-B75DA37C304AQ37278804-7488E238-5D55-4CCD-8806-A46D6CF967B5Q37285199-D19864E8-C95A-477A-A7C2-3489233D9383Q37297222-FE12CD00-8385-48CD-9F44-57C008BEB921Q37612429-C50CFA4B-F3AF-4FEA-85E6-5DACD36EB986Q37706433-8B1EFB5B-0E31-4483-8554-D0A49AFB0C7EQ37996960-953FCA3B-B0A5-4856-964D-2A93CE1174D1Q38172962-D4A059E5-DB2A-4779-A8AE-CF627A72E6B5Q38664824-4FF2E2A3-A266-4D14-9175-F0EC0E670B35Q38881898-0A055929-D6B8-479A-89E0-27397F6EB023Q38891094-2B2BB5A0-7383-448F-8BB4-EB3295FDC8BEQ38901282-415424CE-42DC-4E66-A216-BBA338E1F9AFQ39117000-FFBB82AC-26D8-4FD9-B00C-F28D42637FA3Q40151689-79F46543-24FA-4784-9392-B589EF88B9C1
P2860
Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Placental growth factor and so ...... t and late-onset preeclampsia.
@en
Placental growth factor and so ...... t and late-onset preeclampsia.
@nl
type
label
Placental growth factor and so ...... t and late-onset preeclampsia.
@en
Placental growth factor and so ...... t and late-onset preeclampsia.
@nl
prefLabel
Placental growth factor and so ...... t and late-onset preeclampsia.
@en
Placental growth factor and so ...... t and late-onset preeclampsia.
@nl
P2093
P1476
Placental growth factor and so ...... t and late-onset preeclampsia.
@en
P2093
Matts Olovsson
Peppi Nash
Solveig Nordén-Lindeberg
Ulf J Eriksson
P304
P356
10.1097/01.AOG.0000264552.85436.A1
P407
P577
2007-06-01T00:00:00Z